Botulinum toxin therapy improves masseter spasticity in Amyotrophic Lateral Sclerosis
Autor: | Rabab Debs, T. Lenglet, P.-F. Pradat, N. Le Forestier, M. Mongin, Gaëlle Bruneteau, B. Degos, François Salachas, M.Dm. Amador |
---|---|
Přispěvatelé: | Département de Recherche en Ethique, Université Paris-Sud - Paris 11 (UP11) |
Rok vydání: | 2020 |
Předmět: |
[SDV]Life Sciences [q-bio]
Trismus Injections Intramuscular 03 medical and health sciences 0302 clinical medicine stomatognathic system Tongue medicine Daily living Humans 030212 general & internal medicine Spasticity Amyotrophic lateral sclerosis Botulinum Toxins Type A Retrospective Studies business.industry Medical record Amyotrophic Lateral Sclerosis medicine.disease Botulinum toxin Dental care 3. Good health stomatognathic diseases medicine.anatomical_structure Neurology Muscle Spasticity Anesthesia Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Revue Neurologique Revue Neurologique, Elsevier Masson, 2020, 176, pp.870-873. ⟨10.1016/j.neurol.2020.04.022⟩ |
ISSN: | 0035-3787 |
DOI: | 10.1016/j.neurol.2020.04.022⟩ |
Popis: | Fifteen ALS patients, with troublesome symptoms linked to masseter spasticity, benefited from BoNT-A injections in each masseter. Based on the medical records of patients, the effect of the first injection was assessed one month later. We retrospectively collected information for 12 patients. Eight of them reported a beneficial effect after the injection for the following symptoms: trismus, tongue, lip and cheek biting, and jaw clonus. Five patients indicated that dental care was easier after injection. Our study showed that injections of BoNT-A unequivocally reduced masseter spasticity in ALS patients who subsequently enjoyed greater comfort in their daily living. |
Databáze: | OpenAIRE |
Externí odkaz: |